Results 141 to 150 of about 871,767 (407)
Molecular Oncology, EarlyView.This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest
Respiratory Research, 2018 Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a
Jian Zhou +5 more
doaj +1 more source
The role of circular RNAs in regulating cytokine signaling in cancer
FEBS Open Bio, EarlyView.Cytokines present in the tumor microenvironment fuel cancer development. Aberrant expression of circRNAs contributes to cancer progression. Cytokines are involved in regulating circRNA biogenesis. Furthermore, aberrantly expressed circRNAs regulate the expression of ligands, receptors, and downstream effectors involved in cytokine signaling to promote ...
Vandana Joshi +4 more
wiley +1 more source
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
Revista Brasileira de Hematologia e Hemoterapia, 2011 The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing ...
Roberta Bitencourt +2 more
doaj +1 more source
Matrix: a complex amalgam of structures and functions in tumor microenvironment
FEBS Open Bio, EarlyView.The matrix is a dynamic, intricate three‐dimensional mesh of biomolecules with both structural and functional properties. This review deals with the complexity of this ‘molecular amalgam’ in the tumor microenvironment and highlights its importance in the maintenance and evolution of tumors by describing certain matrix biomolecules, such as ...
Spyros S. Skandalis +3 more
wiley +1 more source
Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity
FEBS Open Bio, EarlyView.This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang +6 more
wiley +1 more source
Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. [PDF]
, 1990 James M. Trevillyan +4 more
openalex +1 more source
Clinical Medicine Insights: Oncology, 2011 The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase.
Marie P. Shieh +2 more
doaj +1 more source
Hematology Reports, 2014 We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well
David Sanford +3 more
doaj +1 more source
Nature Chemistry, 2014 ABL1 tyrosine-kinase inhibitors (TKI) are a front-line therapy for chronic myelogenous leukemia and represent the best known examples of targeted cancer therapeutics.
Dan Fu +8 more
semanticscholar +1 more source